Enrollment, demographics, and clinical features
| Seviprotimut-L | Placebo | |
| N | 230 | 117 |
| Age: median (range) | 58 (18, 80) | 56 (26, 80) |
| Sex: % female | 42 | 44 |
| Race: % white | 99 | 100 |
| Prior melanoma therapy (%) | ||
| Any | 5.2 | 4.3 |
| Radiotherapy | 4.3 | 4.3 |
| Tumor location (%) | ||
| Extremities | 35 | 37 |
| Head and neck | 26 | 21 |
| Trunk | 37 | 41 |
| Other | 2.6 | 0.9 |
| Ethnicity: % Hispanic or Latino | 3 | 3.4 |
| ECOG performance status 0 (%) | 86 | 86 |
| Completed lymphadenectomy (%) | 64 | 64 |
| Median Breslow depth (mm) | 2.8 | 3 |
| T staging (%) | ||
| T0 or TX | 4.8 | 5.1 |
| T1–T2a | 29 | 27 |
| T2b–T4a | 48 | 55 |
| T4b | 18 | 17 |
| N staging (%) | ||
| N0 | 32 | 32 |
| N1a | 36 | 30 |
| N1b–N2b | 19 | 23 |
| N2c/N3 | 13 | 15 |
| Summary AJCC stage (V.7, %) | ||
| IIB/IIC | 32 | 32 |
| IIIA | 30 | 29 |
| IIIB/IIIC | 38 | 39 |
| BRAF mutant* (%) | 35 | 33 |
*BRAF mutation status known for 93%, 96%, and 94% of patients receiving vaccine, placebo, or total. Values shown above are percentages of all.